JP5096169B2 - アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 - Google Patents

アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 Download PDF

Info

Publication number: JP5096169B2
Authority: JP; Japan
Prior art keywords: disease; amyloid; phage; filamentous bacteriophage; pharmaceutical composition
Prior art date: 2005-02-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2007554157A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008528688A (ja

Inventor

ソロモン，ベカ

ゴーレン，オーナ

Original Assignee

ラモット・アット・テルアビブ・ユニバーシティ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-01

Filing date

2006-01-31

Publication date

2012-12-12

2006-01-31 Application filed by ラモット・アット・テルアビブ・ユニバーシティ filed Critical ラモット・アット・テルアビブ・ユニバーシティ

2008-07-31 Publication of JP2008528688A publication Critical patent/JP2008528688A/ja

2012-12-12 Application granted granted Critical

2012-12-12 Publication of JP5096169B2 publication Critical patent/JP5096169B2/ja

2026-01-31 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

208000037259 Amyloid Plaque Diseases 0.000 title claims abstract description 33
238000011282 treatment Methods 0.000 title claims description 22
208000025698 brain inflammatory disease Diseases 0.000 title abstract description 6
206010014599 encephalitis Diseases 0.000 title abstract description 6
210000001642 activated microglia Anatomy 0.000 title abstract description 4
206010061218 Inflammation Diseases 0.000 title description 4
230000004054 inflammatory process Effects 0.000 title description 4
241000724791 Filamentous phage Species 0.000 claims abstract description 79
239000000427 antigen Substances 0.000 claims abstract description 8
108091007433 antigens Proteins 0.000 claims abstract description 8
102000036639 antigens Human genes 0.000 claims abstract description 8
210000004556 brain Anatomy 0.000 claims description 37
201000010099 disease Diseases 0.000 claims description 34
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
208000024827 Alzheimer disease Diseases 0.000 claims description 28
239000004480 active ingredient Substances 0.000 claims description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 17
238000002360 preparation method Methods 0.000 claims description 17
208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 10
208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 10
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 9
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 9
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 9
208000024777 Prion disease Diseases 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
241001515965 unidentified phage Species 0.000 claims description 8
208000008864 scrapie Diseases 0.000 claims description 7
208000034578 Multiple myelomas Diseases 0.000 claims description 6
206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
230000002068 genetic effect Effects 0.000 claims description 6
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
206010022437 insomnia Diseases 0.000 claims description 5
206010023497 kuru Diseases 0.000 claims description 5
231100000518 lethal Toxicity 0.000 claims description 5
230000001665 lethal effect Effects 0.000 claims description 5
208000022099 Alzheimer disease 2 Diseases 0.000 claims description 4
206010002022 amyloidosis Diseases 0.000 claims description 4
208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
230000032683 aging Effects 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
101001018100 Homo sapiens Lysozyme C Proteins 0.000 claims description 2
102100033468 Lysozyme C Human genes 0.000 claims description 2
206010038357 Renal amyloidosis Diseases 0.000 claims description 2
201000007891 familial visceral amyloidosis Diseases 0.000 claims description 2
229920003023 plastic Polymers 0.000 claims description 2
239000004033 plastic Substances 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 abstract description 11
108010090849 Amyloid beta-Peptides Proteins 0.000 description 56
102000013455 Amyloid beta-Peptides Human genes 0.000 description 56
108090000765 processed proteins & peptides Proteins 0.000 description 33
210000004027 cell Anatomy 0.000 description 27
238000000034 method Methods 0.000 description 26
238000004220 aggregation Methods 0.000 description 19
241000699670 Mus sp. Species 0.000 description 18
230000002776 aggregation Effects 0.000 description 17
238000000635 electron micrograph Methods 0.000 description 17
239000002953 phosphate buffered saline Substances 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 17
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 16
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
230000000694 effects Effects 0.000 description 16
102000004196 processed proteins & peptides Human genes 0.000 description 16
235000018102 proteins Nutrition 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
239000000243 solution Substances 0.000 description 15
102000001049 Amyloid Human genes 0.000 description 14
108010094108 Amyloid Proteins 0.000 description 14
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 12
238000003556 assay Methods 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
241000699660 Mus musculus Species 0.000 description 10
239000002552 dosage form Substances 0.000 description 10
230000003993 interaction Effects 0.000 description 10
239000002245 particle Substances 0.000 description 10
230000009467 reduction Effects 0.000 description 10
238000011830 transgenic mouse model Methods 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 9
230000001988 toxicity Effects 0.000 description 9
231100000419 toxicity Toxicity 0.000 description 9
101710125418 Major capsid protein Proteins 0.000 description 8
241000700605 Viruses Species 0.000 description 8
230000003941 amyloidogenesis Effects 0.000 description 8
230000003833 cell viability Effects 0.000 description 8
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
239000010931 gold Substances 0.000 description 8
229910052737 gold Inorganic materials 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 7
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 7
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 7
108020004414 DNA Proteins 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
206010029350 Neurotoxicity Diseases 0.000 description 6
101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 6
206010044221 Toxic encephalopathy Diseases 0.000 description 6
108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 6
FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 6
230000002744 anti-aggregatory effect Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
231100000228 neurotoxicity Toxicity 0.000 description 6
230000007135 neurotoxicity Effects 0.000 description 6
230000008569 process Effects 0.000 description 6
239000013598 vector Substances 0.000 description 6
241000282412 Homo Species 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
239000008298 dragée Substances 0.000 description 5
210000000274 microglia Anatomy 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
241000283707 Capra Species 0.000 description 4
101710132601 Capsid protein Proteins 0.000 description 4
101710169873 Capsid protein G8P Proteins 0.000 description 4
101710094648 Coat protein Proteins 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 4
238000000134 MTT assay Methods 0.000 description 4
231100000002 MTT assay Toxicity 0.000 description 4
101710156564 Major tail protein Gp23 Proteins 0.000 description 4
101710141454 Nucleoprotein Proteins 0.000 description 4
108091000054 Prion Proteins 0.000 description 4
102000029797 Prion Human genes 0.000 description 4
101710083689 Probable capsid protein Proteins 0.000 description 4
229920002472 Starch Chemical class 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000008499 blood brain barrier function Effects 0.000 description 4
210000001218 blood-brain barrier Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
210000000956 olfactory bulb Anatomy 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
238000012545 processing Methods 0.000 description 4
-1 proline Chemical class 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
229930040373 Paraformaldehyde Natural products 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
108010001267 Protein Subunits Proteins 0.000 description 3
102000002067 Protein Subunits Human genes 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000001188 anti-phage Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
238000001493 electron microscopy Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000835 fiber Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
210000002475 olfactory pathway Anatomy 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
238000005063 solubilization Methods 0.000 description 3
230000007928 solubilization Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
239000004474 valine Substances 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
101710138751 Major prion protein Proteins 0.000 description 2
102100025818 Major prion protein Human genes 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000006933 amyloid-beta aggregation Effects 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000001913 cellulose Chemical class 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000008021 deposition Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
230000009881 electrostatic interaction Effects 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
239000002071 nanotube Substances 0.000 description 2
210000002682 neurofibrillary tangle Anatomy 0.000 description 2
210000001517 olfactory receptor neuron Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000004738 parenchymal cell Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000006919 peptide aggregation Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000003498 protein array Methods 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
239000008107 starch Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000010415 tropism Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
230000006974 Aβ toxicity Effects 0.000 description 1
108010051479 Bombesin Proteins 0.000 description 1
102000013585 Bombesin Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101000795849 Calliactis parasitica Delta-hormotoxin-Cpt1b Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108091005944 Cerulean Proteins 0.000 description 1
101800001982 Cholecystokinin Proteins 0.000 description 1
102100025841 Cholecystokinin Human genes 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
108010061642 Cystatin C Proteins 0.000 description 1
102000012192 Cystatin C Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010051021 Eledoisin Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101000573901 Homo sapiens Major prion protein Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010079943 Pentagastrin Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010050254 Presenilins Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
108700028909 Serum Amyloid A Proteins 0.000 description 1
102000054727 Serum Amyloid A Human genes 0.000 description 1
241000219289 Silene Species 0.000 description 1
108010087230 Sincalide Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
102400000096 Substance P Human genes 0.000 description 1
101800003906 Substance P Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
230000003942 amyloidogenic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000008004 cell lysis buffer Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
229920006184 cellulose methylcellulose Polymers 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
229940107137 cholecystokinin Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
239000004020 conductor Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000012866 crystallographic experiment Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000002999 depolarising effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
AYLPVIWBPZMVSH-FCKMLYJASA-N eledoisin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 AYLPVIWBPZMVSH-FCKMLYJASA-N 0.000 description 1
229950011049 eledoisin Drugs 0.000 description 1
238000000295 emission spectrum Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
208000037957 feline spongiform encephalopathy Diseases 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000003517 fume Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000004295 hippocampal neuron Anatomy 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000006993 memory improvement Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000006724 microglial activation Effects 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002241 neurite Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000012466 permeate Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000001044 red dye Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000006918 subunit interaction Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
102000013498 tau Proteins Human genes 0.000 description 1
108010026424 tau Proteins Proteins 0.000 description 1
RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14171—Demonstrated in vivo effect

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

JP2007554157A 2005-02-01 2006-01-31 アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 Expired - Fee Related JP5096169B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64838305P	2005-02-01	2005-02-01
US60/648,383		2005-02-01
PCT/US2006/003291 WO2006083795A1 (en)	2005-02-01	2006-01-31	Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia

Publications (2)

Publication Number	Publication Date
JP2008528688A JP2008528688A (ja)	2008-07-31
JP5096169B2 true JP5096169B2 (ja)	2012-12-12

Family

ID=36589064

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2007554157A Expired - Fee Related JP5096169B2 (ja)	2005-02-01	2006-01-31	アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法

Country Status (13)

Country	Link
US (3)	US7867487B2 (da)
EP (1)	EP1853285B1 (da)
JP (1)	JP5096169B2 (da)
CN (1)	CN101166536B (da)
AT (1)	ATE501723T1 (da)
CY (1)	CY1111455T1 (da)
DE (1)	DE602006020697D1 (da)
DK (1)	DK1853285T3 (da)
ES (1)	ES2363203T3 (da)
PL (1)	PL1853285T3 (da)
PT (1)	PT1853285E (da)
SI (1)	SI1853285T1 (da)
WO (1)	WO2006083795A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007275258A1 (en) *	2006-07-21	2008-01-24	Ramot At Tel Aviv University Ltd.	Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
EP2303315A1 (en)	2008-05-22	2011-04-06	Ramot at Tel Aviv University Ltd.	Method for treating disease characterized by plaque
NZ592928A (en) *	2008-11-24	2012-12-21	Univ Ramot	Method for treating parkinson' s disease using filamentous bacteriophage
WO2012125555A1 (en)	2011-03-11	2012-09-20	Ramot At Tel-Aviv University Ltd.	Method for treating neurodegenerative tauopathy
EP2736522A1 (en) *	2011-07-27	2014-06-04	Neurophage Pharmaceuticals, Inc.	Process for the production of filamentous bacteriophage
WO2013022717A1 (en)	2011-08-05	2013-02-14	Neurophage Pharmaceuticals, Inc.	Pure filamentous bacteriophage and methods of producing same
CA2857539C (en)	2011-11-29	2021-08-03	Neurophage Pharmaceuticals, Inc.	Bacteriophage gene 3 protein compositions and use as amyloid binding agents
WO2013138716A1 (en) *	2012-03-15	2013-09-19	Ramot At Tel-Aviv University Ltd.	The filamentous bacteriophage as an angiogenesis modulator
US9655933B2 (en)	2012-03-15	2017-05-23	Ramot At Tel-Aviv University Ltd.	Filamentous bacteriophage as an angiogenesis modulator
DK2906235T3 (da)	2012-10-02	2017-09-25	Proclara Biosciences Inc	Anvendelse af p3 af bakteriofag-fusionsproteiner som amyloide bindingsmidler
AU2014274253B2 (en) *	2013-05-28	2018-06-14	Proclara Biosciences, Inc.	Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
BR112017011530A2 (pt)	2014-12-03	2018-03-13	Proclara Biosciences Inc	polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU784568B2 (en) *	1999-09-03	2006-05-04	Ramot At Tel-Aviv University Ltd	Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
AU2003205623A1 (en)	2002-01-18	2003-07-30	Cytos Biotechnology Ag	Prion protein carrier-conjugates

2006
- 2006-01-31 DK DK06734085.1T patent/DK1853285T3/da active
- 2006-01-31 CN CN2006800067734A patent/CN101166536B/zh not_active Expired - Fee Related
- 2006-01-31 PT PT06734085T patent/PT1853285E/pt unknown
- 2006-01-31 JP JP2007554157A patent/JP5096169B2/ja not_active Expired - Fee Related
- 2006-01-31 WO PCT/US2006/003291 patent/WO2006083795A1/en not_active Ceased
- 2006-01-31 EP EP06734085A patent/EP1853285B1/en not_active Expired - Lifetime
- 2006-01-31 SI SI200631031T patent/SI1853285T1/sl unknown
- 2006-01-31 DE DE602006020697T patent/DE602006020697D1/de not_active Expired - Lifetime
- 2006-01-31 ES ES06734085T patent/ES2363203T3/es not_active Expired - Lifetime
- 2006-01-31 AT AT06734085T patent/ATE501723T1/de active
- 2006-01-31 PL PL06734085T patent/PL1853285T3/pl unknown
- 2006-01-31 US US11/815,294 patent/US7867487B2/en not_active Expired - Fee Related
2010
- 2010-12-13 US US12/966,786 patent/US8361458B2/en not_active Expired - Fee Related
2011
- 2011-05-16 CY CY20111100462T patent/CY1111455T1/el unknown
2012
- 2012-12-20 US US13/721,468 patent/US20130177533A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK1853285T3 (da)	2011-06-27
US7867487B2 (en)	2011-01-11
US20130177533A1 (en)	2013-07-11
SI1853285T1 (sl)	2011-07-29
CY1111455T1 (el)	2015-08-05
EP1853285B1 (en)	2011-03-16
ATE501723T1 (de)	2011-04-15
WO2006083795A8 (en)	2007-03-15
US20110142803A1 (en)	2011-06-16
WO2006083795A1 (en)	2006-08-10
CN101166536B (zh)	2012-06-27
US8361458B2 (en)	2013-01-29
CN101166536A (zh)	2008-04-23
DE602006020697D1 (de)	2011-04-28
PL1853285T3 (pl)	2011-08-31
EP1853285A2 (en)	2007-11-14
PT1853285E (pt)	2011-06-06
JP2008528688A (ja)	2008-07-31
HK1110790A1 (en)	2008-07-25
ES2363203T3 (es)	2011-07-26
US20090180991A1 (en)	2009-07-16

Legal Events

Date	Code	Title	Description
2009-01-20	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090119
2011-09-07	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110906
2011-12-03	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111202
2011-12-12	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111209
2012-01-07	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120106
2012-03-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120327
2012-06-26	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120625
2012-07-03	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120702
2012-09-07	TRDD	Decision of grant or rejection written
2012-09-12	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120911
2012-09-13	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-09-27	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120920
2012-09-28	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2012-10-01	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20150928 Year of fee payment: 3
2015-10-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-09-27	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-09-28	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
US8361458B2 (en)	2013-01-29	Method and filamentous phage for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
EP2054515B1 (en)	2012-01-11	Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
US20040013647A1 (en)	2004-01-22	Methods and compositions for treating a plaque-forming disease
US20020052311A1 (en)	2002-05-02	Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
JP2003509020A (ja)	2003-03-11	プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
JP6283366B2 (ja)	2018-02-21	アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用
JP2009529320A (ja)	2009-08-20	脳への送達のための抗体および免疫複合体のバインダーとしてのプロテインａをディスプレイする繊維状バクテリオファージ
JP6440765B2 (ja)	2018-12-19	アミロイド結合剤としてのバクテリオファージのｐ３の使用
US20110182948A1 (en)	2011-07-28	Method for treating disease characterized by plaque
CN105473153A (zh)	2016-04-06	包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽
HK1110790B (en)	2011-11-25	Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
Solomon	2020	Bacteriophage Therapies Targets Multiple Diseases Caused by Protein Misfolding